Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. It is day 2 and she is going home today; TWILIGHT supported stopping aspirin after 3 months, but TWILIGHT did not require an acute coronary syndrome, and she has one.
This page helps you decide: Does ticagrelor monotherapy after 3 months hold for an ACS patient like her?
After this page you can
Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.
For Mrs. K., TICO adds acute-coronary-syndrome evidence for the same plan TWILIGHT supported: aspirin plus ticagrelor for 3 months, then ticagrelor alone, with about one net adverse event avoided for every 50 patients: less major bleeding, and no significant difference in ischemic events. TICO's patients were younger (mean 61), Korean, received one stent brand and excluded increased bleeding risk, so for her it is supportive rather than proof. On the one-pager it sits on page 2, in the “Shorter DAPT — what the trials showed” box.